• Gene editing for preventing genetic diseases poses ethical challenges:

ensuring informed consent to avoid coercion and respecting autonomy in decision-making.

Disparities in access based on socioeconomic status or geography raise equity concerns.

Distinguishing therapeutic use from enhancements (e.g., height, intelligence) is crucial ethically.

Risks include off-target mutations and unforeseen health impacts.

Homogenization of genetic traits could reduce diversity.

• Socially,

stigma based on genetic profiles may lead to discrimination and societal divisions,

reshaping norms about disability and desirable traits.

Public perception influenced by media and education impacts acceptance.

• Regulatory frameworks

must involve scientists, ethicists, and policymakers, overseeing research, clinical applications, and commercialization.

Transparency in trials and long-term monitoring are essential. International collaboration is needed for harmonized standards.

Regulatory flexibility is crucial for adapting to technological advancements and evolving ethical considerations, allowing public input and periodic review.

Balancing medical benefits with ethical and social considerations is imperative for responsible gene editing implementation.